**Specifications table**TableSubject area*Cell biology*More specific subject area*Vascular endothelial cells, inflammation, glycosphingolipids, lipid rafts, fatty acid elongase, ceramide synthase*Type of data*Images and tables*How data was acquired*MALDI-TOF MS and real-time PCR*Data format*Raw and analyzed data*Experimental factors*Vascular endothelial cells stimulated by TNF-*α.Experimental features*Lipid raft--enriched cell membranes were prepared by sucrose density gradient centrifugation in the presence of Triton X-100; purified membrane-associated glycosphingolipids were analyzed by MALDI-TOF MS using* α*-CHCA as the matrix.cDNA was prepared from total cellular RNA, and the expression level of target genes was analyzed by real-time PCR using fluorescent-labeled hydrolysis probes.*Data source location*Bioproduction Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, Tsukuba*Data accessibility*The data are available with this article.*Related research article*T. Okuda, et al. Structural characterization and dynamics of globotetraosylceramide in vascular endothelial cells under TNF-α stimulation. Glycoconj. J. 27 (2010)287--296.*[@bib1]

**Value of the data**•The data provide new insights into the molecular dynamics of glycosphingolipids in lipid rafts under inflammatory conditions, which can be of value to researchers in related fields.•Transcriptional up-regulation of *Elovl1* and *Cers5* in response to TNF-α stimulation is a novel finding.•These data can be compared to other scientific data addressing the effects of TNF-α on various cells and tissues.•The data and protocols provided here support other researchers investigating vascular inflammation and glycosphingolipids.

1. Data {#s0005}
=======

For MALDI-TOF MS analyses, lipid raft--enriched membranes (LREMs) of non-treated vascular endothelial cells (ECs) were prepared by sucrose density gradient centrifugation using 1% triton X-100, and fractions enriched in the lipid raft marker flotlline 1 were isolated as the LREM ([Fig. 1](#f0005){ref-type="fig"}). The LREM also partially included the caveolae marker caveolin 1. Glycosphingolipids were purified from the LREM fraction and the molecular composition of globotetraosylceramide (Gb4), a TNF-α--inducible glycosphingolipid in EC [@bib1], was determined by MALDI-TOF MS. In positive-ion mass spectra, molecular ions corresponding to Gb4 were detected: \[M+Na\]^+^ (*m/z* 1249.8--1387.9). A representative mass spectrum of Gb4 in the LREM is shown in [Fig. 2](#f0010){ref-type="fig"}, and the results are summarized in [Table 1](#t0005){ref-type="table"}. Major peaks were detected at *m/z* 1249.8, 1359.9, and 1361.9, corresponding to Gb4 with 4-sphingosine and C16:0 fatty acid, C24:1 fatty acid, and C24:0 fatty acid, respectively. These chemical structures are shown in [Fig. 3](#f0015){ref-type="fig"}. Minor peaks were detected at *m/z* 1333.8 and 1387.9, corresponding to Gb4 with 4-sphingosine and C22:0 fatty acid and C26:1 fatty acid, respectively. The MS data were statistically compared with data pertaining to TNF-α--treated ECs [@bib1]. The intensity of these signals increased uniformly in TNF-α--treated ECs, and the total signal intensity increased significantly, by over 2-fold, compared to that of non-treated ECs. In contrast to the whole cell membrane [@bib1], the ratio of these molecular species of Gb4 was unchanged, and the ratio in the LREM of ECs was close to that in the whole cell membrane of TNF-α--treated ECs [@bib1].Fig. 1Prepared lipid raft--enriched membrane fraction. Lipid raft markers, flotlline 1 and caveolin 1, were detected by immunoblotting, as described in the [Section 2](#s0010){ref-type="sec"}. Actin was used an internal control. LREM, lipid raft--enriched membrane.Fig. 1Fig. 2Representative mass spectrum of Gb4 purified from a lipid raft--enriched membrane.Fig. 2Table 1Mass spectra of Gb4 detected in LREMs.Table 1MSCeramideRelative rate (%)Signal intensity (×10^−3^)\[M+Na\]^+^NonTNFNonTNF1249.8C16:018.25 ± 4.6813.31 ± 5.271.62 ± 0.132.72 ± 1.621333.8C22:010.46 ± 1.7011.39 ± 0.890.98 ± 0.342.32 ± 0.781359.9C24:122.24 ± 3.3126.51 ± 0.732.00 ± 0.175.33 ± 1.591361.9C24:045.36 ± 5.7944.37 ± 5.584.23 ± 1.358.86 ± 2.581387.9C26:13.69 ± 0.403.42 ± 0.740.34 ± 0.100.68 ± 0.21Total9.17 ± 1.9020.1 ± 5.88[\*](#tbl1fnStar){ref-type="table-fn"}[^1][^2]Fig. 3Chemical structures of Gb4 with C16:0 or C24 fatty acids.Fig. 3

For real-time PCR analyses, we examined six candidate genes (*Elovl1, Elovl3, Elovl6, Cers2, Cers5,* and *Cers6*) involved in the synthesis of Gb4 with C16 or C24 fatty acids. *Elovl1* and *Elovl3*, which encode fatty acid elongase 1 and 3, respectively, mediate elongation of C18:0 and C20:1 acyl-CoAs to very-long-chain fatty acids, including C24:0 and C24:1 [@bib2]. *ELovl6* encodes fatty acid elongase 6, which mediates elongation of C16:0 acyl-CoA to C18:0 and C20:1 [@bib2]. The *Cers2* gene encodes ceramide synthase 2, which catalyzes the incorporation of C24:0 and C24:1 acyl-CoAs into sphingosine [@bib3]. *Cers5* and *Cers6* encode ceramide synthase 5 and 6, respectively, which catalyze the incorporation of C16:0 acyl-CoA into sphingosine [@bib3]. Ceramide synthase 5 can dimerize with ceramide synthase 2 to enhance the activity of ceramide synthase 2 [@bib4]. The results of real-time PCR analyses are summarized in [Table 2](#t0010){ref-type="table"}. *Elovl1* transcripts were clearly detected in non-treated ECs, whereas *Elovl3* transcripts were barely detectable, and *Elovl1* expression was significantly up-regulated by TNF-α stimulation. TNF-α stimulation tended to increase the expression of *Cers2*, and significant up-regulation of *Cers5* expression was observed following TNF-α stimulation. These results correlate with increased expression of Gb4 with C24 fatty acids in TNF-α--treated ECs. No significant changes were observed in the expression levels of other target genes, indicating that up-regulated expression of Gb4 with C24 fatty acids is regulated primarily by *Elovl1* and *CerS5*.Table 2Real-time PCR analysis of target gene expression.Table 2Relative expressionTNF/Non*P*-valueNonTNF*Elovl1*3.41 ± 0.7158.64 ± 17.3917.200.008[\*\*](#tbl2fnStarStar){ref-type="table-fn"}*Elovl3*n.d.n.d.*Elovl6*2.66 ± 1.412.96 ± 2.071.110.820*Cers2*0.17 ± 0.042.46 ± 1.5514.750.059*Cers5*0.64 ± 0.0815.97 ± 5.4824.980.011[\*](#tbl2fnStar){ref-type="table-fn"}*Cers6*2.87 ± 0.895.04 ± 1.831.750.095[^3][^4][^5]

2. Experimental design, materials, and methods {#s0010}
==============================================

2.1. Cell culture {#s0015}
-----------------

ECs (HUVEC; KURABO, Osaka, Japan) were maintained in HuMedia-EG2 (KURABO) culture medium, as reported previously [@bib5]. The medium was replaced with fresh HuMedia-EG2 containing 20 ng/ml of TNF-α, and the cells were incubated for 12 or 24 h prior to MALDI-TOF MS or real-time PCR analysis, respectively.

2.2. Preparation of LREMs {#s0020}
-------------------------

The detergent-insoluble membrane fraction was isolated from ECs stimulated with TNF-α using sucrose density gradient centrifugation in the presence of Triton X-100 [@bib1]. Protein markers for caveolae/lipid raft or actin protein in each fraction were detected by immunoblotting using mouse IgG1 monoclonal antibodies (BD Biosciences, Franklin Lakes, NJ), anti-caveolin 1 (mAb 2297), anti-flotilline 1 (mAb 18), and anti-Actin (mAb C4) as appropriate.

2.3. Glycosphingolipid extraction {#s0025}
---------------------------------

Glycosphingolipid extraction from LREM was performed as reported previously [@bib1]. In brief, total lipids from the LREM were sequentially extracted using the chloroform/methanol/water 2:1:0 and 1:2:0.8 (*v*/*v*/*v*), respectively, and glycosphingolipids were separated by column chromatography using Iatrobeads 6RS-8060 (Mitsubishi Kagaku Iatron, Tokyo, Japan).

2.4. MALDI-TOF MS {#s0030}
-----------------

Mass spectrometry analysis of glycosphingolipids was carried out using MALDI-TOF MS according to a previously published method [@bib1].

2.5. Real-time PCR {#s0035}
------------------

Real-time PCR analyses were performed as reported previously [@bib6] with slight modifications which used fluorescent-labelled hydrolysis probes. Amplification and quantification of target gene cDNAs were performed using a Light Cycler® 480 II system with gene-specific primers, single hydrolysis probes (Universal ProbeLibrary Probes; Roche, Basel, Switzerland) and a reaction mixture containing Light Cycler® 480 Probe Master (Roche), according to the manufacturer׳s instructions. The gene-specific primers and single hydrolysis probes used in this study are summarized in [Table 3](#t0015){ref-type="table"}.Table 3Primers and probes used for real-time PCR analyses.Table 3Gene (number[a](#tbl3fna){ref-type="table-fn"})Primer sequenceProbe sequence (Probe number[b](#tbl3fnb){ref-type="table-fn"})*Elovl1Forward: 5*′*-ACTTCTCTCTGGCCCTGCTGGATGGAG*([NM_022821](ncbi-n:NM_022821){#ir0005})*Reverse: 5*′*-TCACCTCTTGGTACAAGTTCACA(\#58)Elovl3Forward: 5*′*-AACCTGCAAGGGCCTCTCCTTCTGCC*([NM_152310](ncbi-n:NM_152310){#ir0010})*Reverse: 5*′*-TAATGCCCCACATCCTCACT(\#29)Elovl6Forward: 5*′*-TTTGAACTGAGGAAGCCATTAGTCTGGTCTC*([NM_024090](ncbi-n:NM_024090){#ir0015})*Reverse: 5*′*-CAGTTCGAAGAGCACCGAAT(\#54)Cers2Forward: 5*′*-AGACGGAGTACACGGAGCAGGCTCCAGA*([NM_022075](ncbi-n:NM_022075){#ir0020})*Reverse: 5*′*-CGTTCCCACCAGAAGTAATCA(\#50)Cers5Forward: 5*′*-CACATCCTCTCGGTGTTCCGGCGGCGG*([NM_147190](ncbi-n:NM_147190){#ir0025})*Reverse: 5*′*-CAGGGTTTGGCAATAAATCG(\#70)Cers6Forward: 5*′*-TCATGATTCAGCTGATGCTCTTGGAGGCTG*([NM_203463](ncbi-n:NM_203463){#ir0030})*Reverse: 5*′*-CACATTTTCTGAAACTTGGCATA(\#75)St3gal5*Forward: 5′-CTGCCTTTGACATCCTTCAGTCTGGGGCC([NM_003896](ncbi-n:NM_003896){#ir0035})Reverse: 5′-CGATTGTGGGGACGTTCTTA(\#57)[^6][^7]

2.6. Statistical analysis {#s0040}
-------------------------

After determination of variance by the *F*-test, statistical significance was determined using the two-tailed Student׳s *t*-test, with statistical significance defined as follows: \**P* \< 0.05, \*\**P* \< 0.01.
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=============================================
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[^1]: Means ± S.D.; *n* = 3.

[^2]: *P* \< 0.05, non-treated cells vs TNF-α--treated cells. Non, non-treated cells; TNF, TNF-α--treated cells.

[^3]: The relative expression of target genes is shown as the ratio of expression relative to that of the internal control gene, *St3gal5*. As the level of *St3gal5* expression in non-treated and TNF-α--treated ECs was more stable than that of general reference genes (*Gapdh* and *Actb*), it was used as the internal control in this experiment. Mean ± S.D.; *n* = 4 from two independent experiments.

[^4]: *P*\< 0.05,

[^5]: *P* \< 0.01, non-treated vs TNF-α--treated. Non, non-treated cells; TNF, TNF-α--treated cells; n.d., not detected.

[^6]: Genbank accession number (<http://www.ncbi.nlm.nih.gov/>).

[^7]: Probe number from the Universal Probe Library (Roche).
